Product Details

Uniprot No.

Target Names

Alternative Names

Histone-lysine N-methyltransferase EZH2 (EC 2.1.1.43) (ENX-1) (Enhancer of zeste homolog 2) (Lysine N-methyltransferase 6), EZH2, KMT6

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human KMT6 / EZH2

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

10H8

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IHC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200

Protocols

ELISA Protocol
Immunohistochemistry (IHC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

EZH2 (Enhancer of Zeste Homolog 2) serves as the catalytic subunit of Polycomb Repressive Complex 2, where it functions as a histone-lysine N-methyltransferase responsible for trimethylating histone H3 at lysine 27. This epigenetic modification establishes transcriptionally repressive chromatin states that govern cell fate decisions, differentiation, and proliferation. Dysregulation of EZH2 has emerged as a significant factor in oncogenesis, with overexpression and gain-of-function mutations documented across numerous malignancies, making it both a compelling research target and a therapeutic point of intervention.

This recombinant monoclonal antibody, generated against a synthetic peptide derived from human EZH2, offers the reproducibility advantages inherent to recombinant technology. Because the antibody sequence is defined and expressed consistently, researchers can expect reliable performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations.

Validation in immunohistochemistry demonstrates effective detection in paraffin-embedded human colon cancer tissue, with optimal staining achieved at dilutions between 1:50 and 1:200. The validation protocol employed citrate buffer antigen retrieval at pH 6.0 under high pressure, followed by overnight primary antibody incubation at 4°C and detection via HRP-conjugated goat anti-rabbit polymer with DAB visualization. This established workflow provides a reliable starting point for researchers examining EZH2 expression patterns in archival tissue specimens.

For investigators studying epigenetic mechanisms in cancer biology, chromatin regulation, or evaluating EZH2 as a biomarker in tumor samples, this antibody provides a dependable tool for immunohistochemical analysis of human tissues.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

Gene References into Functions

EZH2 interacts with PCNA and dimethylates PCNA at lysine 110. Dimethylation of PCNA is essential for DNA polymerase delta binding to PCNA and DNA replication. PMID: 30071900
Mechanistic studies in human breast cancer cell lines revealed that miR-92b directly targeted EZH2 promoting autophagy, and inhibiting the viability and invasion of breast cancer cells. PMID: 30066891
HOXD-AS1 could interact with EZH2, and then repress p57 expression, to aggravate osteosarcoma oncogenesis. PMID: 30119259
p38-mediated phosphorylation at threonine 367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. PMID: 30022044
Study suggests the higher expressions of HOTAIR and EZH2 among three breast cancer cell lines. HOTAIR could bind specifically to EZH2 and PTEN, highlighting the capability of HOTAIR to inhibit the expression of PTEN by recruiting EZH2 in breast cancer. Downregulation of HOTAIR or silencing of EZH2 was noted to inhibit the proliferation, invasion, and migration of breast cancer cells, while promoting their apoptosis. PMID: 30048163
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program driven by FOXC1. PMID: 29959321
Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors PMID: 29438697
The EZH2 expression is decreased in multiple sclerosis patients PMID: 30367633
EZH2 regulates the expression of miR-139-5p via H3K27me3, and the EZH2/miR-139-5p axis participates in the progression of Pancreatic cancer. PMID: 30304920
data demonstrated that in brain glioma cells, the decrease of EZH2 level could suppress cell proliferation and tumorigenesis potency, and meanwhile inhibit the expressions of oncogenes including c-myc and Akt. PMID: 30305602
In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac). PMID: 29371630
FOXP4-AS1 is overexpressed in osteosarcoma (OS), and is the independent risk factor in OS prognosis. Upregulated FOXP4-AS1 promotes the proliferation, migration and cell cycle, but inhibits apoptosis of OS cells. Furthermore, FOXP4-AS1 participates in the development and progression of OS by downregulating LATS1 via binding to LSD1 and EZH2. PMID: 29859193
High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with prostate cancer, at diagnosis. PMID: 29174711
High EZH2 expression is associated with high-grade upper tract urothelial carcinoma. PMID: 29748098
Enhancer of Zeste Homolog 2 (EZH2), SET domain, bifurcated 1 protein (SETDB1), lysine-specific histone demethylase 1 (LSD1), histone H3 methylation (H3K9me3 and H3K27me3) expression are altered in colorectal cancer (CRC) and may play a role in colorectal carcinogenesis. PMID: 30105513
Data show that miR-1301 inhibited the expression of enhancer of zeste homolog 2 protein (EZH2) by binding to the 3' untranslated regions (3'-UTR) of EZH2 gene. PMID: 29790898
We characterized a lncRNA, PCa specific expression and EZH2-associated transcript (PCSEAT, annotated as PRCAT38), which is specifically overexpressed in prostate cancer. PCSEAT promotes cell proliferation, at least in part by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2. PMID: 29803673
Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells. PMID: 29185157
these data indicate that RING1B and EZH2 repress the innate inflammatory cutaneous squamous cell carcinoma function and impair tumor immunosurveillance PMID: 29394319
The interaction of methyltransferase EZH2 or demethylase JMJD3 on RGMA, RARb2, AR, PGR, and ERa genes in the progression and aggressiveness of prostate cancer. PMID: 29161520
Results show that EZH2 expression was significantly higher in lung adenocarcinoma (LA) and that EZH2 promotes LA cell invasion and metastasis by inhibiting SPRY4-IT1 expression. PMID: 28796375
Study identifies the residues on EZH2 that are critical for its interaction with VAV and demonstrate that EZH2 interactions with VAV proteins are crucial for the regulation of adhesion dynamics and cellular transformation. PMID: 28967906
Study shows that EZH2 contributes to PARP inhibitors sensitivity in breast cancer cells. Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2. PMID: 28925391
Primary cutaneous follicle center lymphomas with concomitant 1p36 deletion and TNFRSF14 mutations frequently express high levels of EZH2 protein. PMID: 29858685
Curcumol inhibits proliferation and induces apoptosis by targeting EZH2. PMID: 29852354
EZH2, ET-1, and CD34 may act as biomarkers of aggressive cervical squamous cell carcinoma PMID: 29630085
the hsa_circ_0071589/miR-600/EZH2 axis may play critical regulatory roles in the pathogenesis of colorectal cancer. PMID: 29710537
EZH2 mutations coexisted with mutations of NOTCH1, IL7R, and PHF6 in the two Adult T-cell Acute Lymphoblastic Leukemia patients, and they responded poorly to chemotherapy and experienced difficult clinical histories and inferior outcomes PMID: 28747286
An explicit oncogenic role of TP73-AS1 in the NSCLC tumorigenesis, suggesting a TP73-AS1-miR-449a-EZH2 axis and providing new insight for NSCLC tumorigenesis. PMID: 29803931
results show the effect of individual O-GlcNAcylation sites on the function of EZH2 and suggest an alternative approach to tumor suppression through selective inhibition of EZH2 O-GlcNAcylation. PMID: 29941599
High EZH2 expression is associated with gastric cancer. PMID: 30031062
combined panel had the highest sensitivity and specificity at 96.3% and 100%, which was significantly or marginally higher than those of EZH2, C-KIT, and CD205 alone PMID: 29487009
EZH2 positivity was significantly correlated with WHO tumor grade and worse prognosis in gliomas. PMID: 28862715
Long non-coding RNA H19 was found to play an oncogenic role in oral squamous cell carcinoma cells by regulating EZH2 and by targeting miR138. PMID: 29344674
In univariable analysis, patients carrying mutations in DNMT3A, U2AF1, and EZH2 had worse overall and relapse-free survival. PMID: 29321554
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. PMID: 29358618
The results indicated that when STAT3 signaling activity was attenuated by Stattic or enhanced with a STAT3 plasmid, the EZH2/miR-200 axis was markedly altered, thus resulting in modulation of the invasion and migration of OSCC cell lines. PMID: 29532870
Data suggest the polycomb repressive complex 2 subunits EZH2, SUZ12, and EED protein axis as promising therapeutic target for treating sarcoma. PMID: 29415665
Results demonstrate that EZH2 inhibition enhances HCC eradication by NK cells and that EZH2 functions, in part, as an oncogene by inhibiting immune response. PMID: 29581297
Heat-treated human dermal fibroblast exhibited a reduction in lncRNA LET expression and increase in EZH2 expression. PMID: 29393360
EZH2 rs12670401 and rs6464926 polymorphisms, EZH2 and SMYD3 expression, clinical staging, lymph node metastasis, human epidermal growth factor receptor-2 (HER2) status, and metastasis may be correlated with breast cancer susceptibility and prognosis. PMID: 29089464
These data inferred that long non-coding RNA PVT1 could be served as an indicator of glioma prognosis, and PVT1-EZH2 regulatory pathway may be a novel therapeutic target for treating glioma. PMID: 29046366
Enhancer of zeste homolog 2 (EZH2) overexpression is associated with malignant potential in thyroid cancer, and may thus be a useful prognostic marker of aggressive thyroid cancer. PMID: 29275295
EZH2 increases STAT3 phosphorylation and upregulates the expression of 72 kDa type IV collagenase and overexpression of EZH2 was demonstrated to increase the proliferation and invasive potential of renal cell carcinoma cells. PMID: 29286132
High glucose enhances the formation of EZH2/Snail/HDAC1 complex in the nucleus, which in turn causes E-cadherin repression. PMID: 29705809
Patients with all of the following: the tumor size PMID: 28738014
Upregulation of circRNA BCRC4 promoted apoptosis and inhibited viability of bladder cancer cells, up-regulated BCRC4-increased miR-101 level, which suppressed EZH2 expression in both RNA and protein levels. PMID: 29270748
Our data demonstrates that EZH2 participates in Glioblastoma multiforme-induced immune deficient and EZH2 suppression in Glioblastoma multiforme can remodel microglia immune functions PMID: 29132376
Coexistence of BRAF V600E mutation and EZH2 gain is rather prevalent in melanoma. PMID: 29202777
MiR-4465 suppressed cancer cells proliferation and metastasis by directly targeting the oncogene EZH2. PMID: 29169732

Hide All

Involvement in disease

Weaver syndrome (WVS)

Subcellular Location

Nucleus.

Protein Families

Class V-like SAM-binding methyltransferase superfamily, Histone-lysine methyltransferase family, EZ subfamily

Tissue Specificity

In the ovary, expressed in primordial follicles and oocytes and also in external follicle cells (at protein level). Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis.

Database Links

HGNC: 3527

OMIM: 277590

KEGG: hsa:2146

STRING: 9606.ENSP00000320147

UniGene: Hs.444082

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA218051A0HU
Size	US$210
	Order now
Image	IHC image of CSB-RA218051A0HU diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions?	Leave a Message or Start an on-line Chat

EZH2 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background